1
|
Boulon C, Aiouaz S, Blaise S, Mangin M, Decamps-Le Chevoir J, Senet P, Lazareth I, Baudot N, Tribout L, Imbert B, Lapebie FX, Lacroix P, Truchetet ME, Seneschal J, Solanilla A, Skopinski S, Lazaro E, Quéré I, Pistorius MA, Le Hello C, Perez P, Carpentier P, Constans J. Correlation between capillaroscopic classifications and severity in systemic sclerosis: results from SCLEROCAP study at inclusion. Clin Exp Rheumatol 2019; 37 Suppl 119:63-68. [PMID: 31172926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2019] [Accepted: 04/01/2019] [Indexed: 06/09/2023]
Abstract
OBJECTIVES We assessed the correlation between severity of systemic sclerosis (SSc) and current staging systems based on nailfold capillaroscopy. METHODS SCLEROCAP is a multicenter prospective study including consecutive scleroderma patients who have a yearly routine follow-up with capillaroscopy and digital blood pressure measurement. Capillaroscopy images were read by two observers blinded from each other, then by a third one in the case of discordance. A follow-up of 3 years is planned. The present study assessed the correlation between severity of systemic sclerosis (SSc) and current staging systems based on nail fold capillaroscopy at enrollment in the SCLEROCAP study. Univariate and multivariate logistic regression analysis was performed for both the Maricq and Cutolo classifications. RESULTS SCLEROCAP included 387 patients in one year. Maricq's active and Cutolo's late classifications were very similar. In multivariate analysis, the number of digital ulcers (OR for 2 ulcers or more, respectively 2.023 [1.074-3.81] and 2.596 [1.434-4.699]) and Rodnan's skin score >15 (OR respectively 32.007 [6.457-158.658] and 18.390 [5.380-62.865]) correlated with Maricq's active and Cutolo's late stages. Haemoglobin rate correlated with Cutolo's late stage (hemoglobin<100 vs. >120 g/dl: OR 0.223 [0.051-0.980]), and total lung capacity with Maricq's active one: increase in 10%: OR0.833 [0.717-0.969]. CONCLUSIONS The correlations found between capillaroscopy and severity of SSc are promising before the ongoing prospective study definitively assesses whether capillaroscopy staging predicts complications of SSc. Only two capillaroscopic patterns seem useful: one involving many giant capillaries and haemorrhages and the other with severe capillary loss.
Collapse
Affiliation(s)
- Carine Boulon
- Service de Médecine Vasculaire, Hôpital Saint-André, Bordeaux, France
| | - Soraya Aiouaz
- Unité de Soutien Méthodologique à la Recherche Clinique, Pôle de Santé Publique, CHU de Bordeaux, France
| | - Sophie Blaise
- Hôpital Universitaire de Grenoble, Département de Médecine Vasculaire, Grenoble, France
| | - Marion Mangin
- Service de Médecine Vasculaire, Hôpital Saint-André, Bordeaux, France
| | | | - Patricia Senet
- Service de Dérmatologie, Médecine Vasculaire et Allergologie, Hôpital Tenon, Paris, France
| | | | - Nathalie Baudot
- Service de Dérmatologie, Médecine Vasculaire et Allergologie, Hôpital Tenon, Paris, France
| | - Laurent Tribout
- Service de Dérmatologie, Médecine Vasculaire et Allergologie, Hôpital Tenon, Paris, France
| | - Bernard Imbert
- Hôpital Universitaire de Grenoble, Département de Médecine Vasculaire, Grenoble, France
| | | | | | | | | | - Anna Solanilla
- Service de Médecine Interne, Clinique Mutualiste de Lesparre, France
| | - Sophie Skopinski
- Service de Médecine Vasculaire, Hôpital Saint-André, Bordeaux, France
| | - Estibaliz Lazaro
- Service de Médecine Interne et Maladies Infectieuses, Hôpital Haut-Lévêque, Pessac, France
| | - Isabelle Quéré
- Service de Médecine Vasculaire, Hôpital Saint Eloi, Montpellier, France
| | | | - Claire Le Hello
- Service de Médecine Vasculaire, CHU Nord Saint-Etienne, Université Jean Monnet, Campus Santé et Innovations, Saint-Etienne, France
| | - Paul Perez
- Unité de Soutien Méthodologique à la Recherche Clinique, Pôle de Santé Publique, CHU de Bordeaux, France
| | | | - Joel Constans
- Service de Médecine Vasculaire, Hôpital Saint-André, Bordeaux, France.
| |
Collapse
|
2
|
Benzidia I, Connault J, Solanilla A, Michon-Pasturel U, Jamelot M, Nguessan MK, Hij A, Le Maignan C, Farge D, Frère C. [New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application]. J Med Vasc 2017; 42:375-383. [PMID: 29203044 DOI: 10.1016/j.jdmv.2017.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2017] [Accepted: 09/17/2017] [Indexed: 06/07/2023]
Abstract
Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients, and the second leading cause of death in this setting. Cancer patients are also more likely to present recurrent VTE and major bleeding while taking anticoagulants. Management of VTE in these patients is always challenging and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cancer (ITAC-CME) released international guidelines for the treatment and prophylaxis of VTE and central venous catheter-associated thrombosis, based on a systematic review of the literature ranked according to the Grading of Recommendations Assessment, Development, and Evaluation scale. An update of these ITAC-CME consensus guidelines, including the use of direct oral anticoagulants, was recently published. In this review, we summarize these updated guidelines. Better adherence to the international guidelines, involving an adequate educational and active implementation strategies, will substantially decrease the burden of VTE and allow to increase survival in cancer patients.
Collapse
Affiliation(s)
- I Benzidia
- UF04 maladies auto-immunes et pathologie vasculaire, service de médecine interne, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - J Connault
- Service de médecine interne, CHU de Nantes, 44000 Nantes, France
| | - A Solanilla
- Service de médecine vasculaire, hôpital Saint-André, 33076 Bordeaux, France
| | - U Michon-Pasturel
- Service de médecine vasculaire, groupe hospitalier Paris Saint-Joseph, 185, rue Raymond-Losserand, 75014 Paris, France
| | - M Jamelot
- Service d'oncologie médicale, centre Henri-Becquerel, rue d'Amiens, 76000 Rouen, France
| | - M K Nguessan
- Département de médecine interne et gériatrie, centre hospitalier universitaire de Treichville, université Félix Houphouet Boigny d'Abidjan, Abidjan, Côte d'Ivoire
| | - A Hij
- UF04 maladies auto-immunes et pathologie vasculaire, service de médecine interne, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - C Le Maignan
- Service d'oncologie médicale, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - D Farge
- UF04 maladies auto-immunes et pathologie vasculaire, service de médecine interne, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France
| | - C Frère
- Service d'hématologie biologique, hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
| |
Collapse
|
3
|
Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012; 167:1138-44. [PMID: 23039171 DOI: 10.1111/j.1365-2133.2012.11186.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Imatinib mesylate is a potent inhibitor of platelet-derived growth factor and transforming growth factor-β signalling pathways which may play a role in systemic sclerosis (SSc)-associated skin changes. OBJECTIVES We aimed primarily at assessing the efficacy of imatinib mesylate in scleroderma skin fibrosis. METHODS We performed a phase II double-blinded trial on patients with scleroderma with either morphoea involving > 20% of body surface area or SSc with extensive skin involvement: modified Rodnan Skin Score (mRSS) ≥ 20/51. Each patient was randomized to receive either imatinib mesylate 400 mg or placebo daily for a total of 6 months, and then was followed up 6 months after therapy discontinuation. Skin fibrosis was assessed by mRSS and measurement of the dermal thickness using skin biopsies performed at inclusion and at 6 months of treatment. In addition, quality of life (Dermatology Life Quality Index and modified Health Assessment Questionnaire for Scleroderma) was recorded at each visit, and pulmonary function before and after intervention. RESULTS Twenty-eight patients were included in the study with a mean age of 48·9 years (range 30-71): 25 had a diagnosis of a SSc and three of diffuse cutaneous scleroderma. Demographic data, frequency of organ involvement of SSc and mRSS were comparable between groups. At 6 months, the proportion of variation of mRSS from inclusion was not statistically significantly different between the two groups (median +0·10 in imatinib group vs. -0·16 in placebo group, P = 0·098). Similarly, changes in dermal thickness, quality of life and diffusion capacity for carbon monoxide were not significantly different between groups. CONCLUSIONS This study failed to demonstrate the efficacy of imatinib 400 mg daily to improve skin fibrosis of diffuse scleroderma after 6 months of treatment based on validated outcome measurements.
Collapse
Affiliation(s)
- S Prey
- Department of Dermatology, Hôpital Saint André, CHU de Bordeaux, 1 rue Jean Burguet, 33075 Bordeaux, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Jeanneau D, Boulon C, Solanilla A, Constans J, Conri C. Syndrome des ongles jaunes. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.03.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Viguier JB, Solanilla A, Boulon C, Constans J, Conri C. [Digital ischemia in two patients treated with gemcitabine]. ACTA ACUST UNITED AC 2010; 35:185-8. [PMID: 20116189 DOI: 10.1016/j.jmv.2009.12.032] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2009] [Accepted: 12/10/2009] [Indexed: 11/17/2022]
Abstract
A 73-year-old man with an urothelial carcinoma treated with gemcitabine and carboplatinium and an 84-year-old man with a mesothelioma treated with gemcitabine alone developed digital ischemia. In the first patient, the ischemia involved all fingers except the thumbs during the second cycle of treatment. The ischemia developed during the first cycle in the second patient and involved the right major and ring fingers. In the literature, gemcitabine vascular toxicity is probably potentialized by platinium salts. Several nosological entities occur simultaneously. The most widely described involve isolated digital ischemia for doses to the order of 3000mg, and a hemolytic and uremic thrombotic microangiopathy for gemcitabine doses above 10,000mg. The vascular toxicity of platinium salts is not dose-dependent. In these two patients, the clinical course was favorable with interruption of the chemotherapy, treatment by iloprost and aspirin.
Collapse
Affiliation(s)
- J-B Viguier
- Service de médecine interne et vasculaire, centre hospitalier Robert-Boulin, rue de la Marne, Libourne cedex, France.
| | | | | | | | | |
Collapse
|
6
|
Viguier JB, Amraoui S, Solanilla A, Boulon C, Constans J, Conri C. [An image of vena cava thrombosis]. ACTA ACUST UNITED AC 2009; 34:372-3. [PMID: 19717254 DOI: 10.1016/j.jmv.2009.07.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2009] [Accepted: 07/23/2009] [Indexed: 10/20/2022]
Affiliation(s)
- J-B Viguier
- Service de médecine vasculaire et interne, hôpital Saint-André, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.
| | | | | | | | | | | |
Collapse
|
7
|
Vircoulon M, Boulon C, Guisset O, Solanilla A, Constans J, Conri C. Aspergillose pulmonaire invasive chez l’immunocompétent. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.03.333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Solanilla A, Ducroix JP, Conri C, Constans J, Sevestre MA. Intérêt de la thérapie cellulaire à visée angiogénique dans la sclérodermie systémique avec artériopathie oblitérante : à propos d’un cas clinique. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.03.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Solanilla A, Boulon C, Constans J, Conri C. Embols systèmiques multiples chez un adulte jeune. Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.03.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Constans J, Boulon C, Solanilla A, Conri C. Conséquences thérapeutiques de la mise en évidence d’une thrombophilie. Rev Med Interne 2008; 29:486-90. [DOI: 10.1016/j.revmed.2008.02.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2007] [Revised: 12/24/2007] [Accepted: 02/12/2008] [Indexed: 10/22/2022]
|
11
|
Monge M, Vaida I, Modeliar SS, Solanilla A, Airapetian N, Presne C, Makdassi R, Fournier A, Choukroun G. Retroperitoneal hematoma compressing a single functioning kidney: an unusual cause of obstructive renal failure. Clin Nephrol 2007; 67:318-20. [PMID: 17542341 DOI: 10.5414/cnp67318] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
We report a case of a retroperitoneal hematoma occurring in a patient under anticoagulation therapy for deep-venous thrombosis and presenting as an anuric acute renal failure. A coexisting polycythemia vera led to misdiagnosis that could have been life-threatening. A woman, known for polycythemia vera and a single functioning right kidney, was admitted with mild abdominal pain in a context of recent deep venous thrombosis under low-molecular weight heparin. Clinical examination revealed hepatomegaly associated with polycythemia vera. Biochemical evaluation disclosed an acute renal failure, and renal ultrasonography showed no dilation of the renal pelvis. Retroperitoneal hematoma resulted in shock, progressive anemia and obstructive renal failure, related to renal pelvic compression. A right renal indwelling catheter was introduced to restore urine flow after one hemodialysis session, and an inferior vena cava filter was placed because of anti-coagulation contra-indication. However, pulmonary embolism occurred, so that oral anticoagulants were introduced. The hematoma resorbed spontaneously, and a year after this episode, the patient is still alive and well. Retroperitoneal hematoma is a rare cause of obstructive acute renal failure and a life-threatening complication of anti-coagulation therapy.
Collapse
Affiliation(s)
- M Monge
- Department of Nephrology, Internal Medicine and Intensive Care Unit, Amiens University Hospital Av R Laennec, 80054 Amiens, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Solanilla A, Déchanet J, El Andaloussi A, Dupouy M, Godard F, Chabrol J, Charbord P, Reiffers J, Nurden AT, Weksler B, Moreau JF, Ripoche J. CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells. Blood 2000; 95:3758-64. [PMID: 10845907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
CD40 ligand (CD40L)/CD40 interactions play a central role in T-cell-dependent B-cell activation as previously shown by in vitro studies, the phenotype of CD40L knockout mice and the defective expression of CD40L in patients who have X-linked immunodeficiency with hyper-IgM. The distribution of CD40 in cells other than of myeloid and lymphoid lineages has suggested additional functions for this receptor/ligand couple. Here we show that CD40L stimulates myelopoiesis with a noticeable effect on megakaryocytopoiesis in cocultures of hematopoietic progenitor cells and bone marrow stromal cells. These results suggest a mechanism by which T-cell or platelet-associated or soluble CD40L may regulate myelopoiesis. (Blood. 2000;95:3758-3764)
Collapse
Affiliation(s)
- A Solanilla
- FR 60, Biologie des Greffes, Université de Bordeaux 2; ETS Franche Comté, Besançon, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Solanilla A, El Andaloussi A, Grosset C, Duchez P, Mossalayi MD, Mahon FX, Reiffers J, Marit G, Ripoche J. Differential effect of interferon alpha on chronic myelogenous leukaemia and normal haematopoietic progenitors in a stromal cell co-culture context: role of the flt3 ligand. Br J Haematol 2000; 109:382-7. [PMID: 10848829 DOI: 10.1046/j.1365-2141.2000.01917.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Interferon alpha (IFN-alpha) is used to treat chronic myelogenous leukaemia (CML) patients. However, its target(s) remain(s) unknown. One possibility is that there is a differing sensitivity of the leukaemic from the normal colony-forming cell (CFC) compartments to IFN-alpha. Co-cultures of progenitors with stromal cells provide a valuable tool to dissect direct and indirect activities of IFN-alpha. In this study, we have used endothelial cells (EC) as a source of stromal cells. In co-cultures of normal progenitors with EC, IFN-alpha increased the generation of clonogenic cells, mainly via an increased production of flt3 ligand (FL) by EC. In contrast, in co-cultures of CML progenitors with EC, IFN-alpha inhibited the generation of clonogenic cells, mainly by direct inhibition on the progenitors, the up-regulation of FL production by stromal cells being unable to compensate for the direct inhibitory effects of IFN-alpha. These data provide evidence for a differential effect of IFN-alpha on the growth of CML and normal CFC cells in a stromal context and suggest that an alteration in the response of CML progenitor cells to FL is important in the explanation of this differential effect.
Collapse
Affiliation(s)
- A Solanilla
- FR 60, Biologie des Greffes, Université de Bordeaux 2, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Solanilla A, Grosset C, Lemercier C, Dupouy M, Mahon FX, Schweitzer K, Reiffers J, Weksler B, Ripoche J. Expression of Flt3-ligand by the endothelial cell. Leukemia 2000; 14:153-62. [PMID: 10637491 DOI: 10.1038/sj.leu.2401635] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Flt3-ligand (FL) is a cytokine that is of paramount importance in the proliferation of primitive hematopoietic progenitors. In this study, we show that endothelial cells (EC) produce large amounts of soluble FL and express a membrane-bound form of the molecule. Bone marrow microvascular EC also produce FL, suggesting that EC are an important source of FL in the bone marrow. High concentrations of FL in EC supernatants contrast with its undetectable levels in long-term bone marrow cultures. A single mRNA for FL is detected, suggesting that soluble FL derives from the membrane-bound species by proteolytic release. FL mRNA is stable with a half-life of about 3 h. II-1alpha increases FL mRNA levels and membrane and soluble FL expression. Glucocorticoids, known inhibitors for many hematopoietic growth factors do not down-regulate the expression of FL. On the contrary, GC increase the expression of both species of FL. The neutralization of FL in cocultures EC/ hematopoietic progenitors results in an acceleration of the maturation of the progenitors. IFN-alpha, MIP-1 alpha and TGF-beta stimulate production of membrane-bound and soluble FL. This stimulation is essential to explain their modulatory effect on the generation of clonogenic cells in cocultures EC/hematopoietic progenitors. Leukemia (2000) 14, 153-162.
Collapse
Affiliation(s)
- A Solanilla
- Laboratoire de Greffe de Moelle, Université Victor Ségalen, Bordeaux, France
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Jazwiec B, Solanilla A, Grosset C, Mahon FX, Dupouy M, Pigeonnier-Lagarde V, Belloc F, Schweitzer K, Reiffers J, Ripoche J. Endothelial cell support of hematopoiesis is differentially altered by IL-1 and glucocorticoids. Leukemia 1998; 12:1210-20. [PMID: 9697875 DOI: 10.1038/sj.leu.2401086] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We investigated the ability of endothelial cells (EC) to support hematopoiesis in contact and non-contact cocultures with isolated CD34+ or CD34/CD38low cells. In the absence of exogenous cytokines, umbilical vein EC (HUVEC) efficiently support proliferation of hematopoietic cells and generation of colony-forming cells (CFC). Cytokines (IL-6, LIF, G-CSF, GM-CSF, M-CSF, but not IL-1, IL-3, IL-7) were detected in HUVEC coculture supernatants. Neutralization of these cytokines profoundly inhibited the ability of EC supernatants to support the differentiation of hematopoietic progenitors and led to an accumulation of immature cells. Contact cocultures were significantly more efficient than non-contact cocultures. The expanded cell population essentially belonged to the myeloid and monocytic lineages. Contact cocultures generated cells expressing the CD61 or CD41 antigens. Interleukin-1alpha (IL-1alpha) augmented EC capacity to support hematopoiesis, this property resulting from the upregulation of cytokine expression. Glucocorticoids (GC) reduced this capacity by downregulating the biosynthesis of cytokines by EC and not by a direct effect on the progenitor cells. EC from the bone marrow microvasculature (BMEC) support the proliferation and the differentiation of hematopoietic progenitors. Synergistic increase in progenitor cells expansion and generation of CFC occurred when EC cocultures were added with exogenous cytokines. Supernatants of IL-1alpha-stimulated EC potentiated the effects of an association of IL-1, IL-3, IL-6, LIF, SCF, Flt3-ligand, TPO, G-CSF, GM-CSF, M-CSF and IL-11 on the proliferation of hematopoietic progenitors suggesting that EC may produce other soluble growth factors potentiating the action of the above set of cytokines.
Collapse
Affiliation(s)
- B Jazwiec
- Laboratoire de greffe de moelle, UMR 5540, Université de Bordeaux II, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|